Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 301 publications.

Herring W, Ciarametaro M, Mauskopf J, Wamble D, Sils B, Dubois R. What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States. Expert Rev Pharmacoecon Outcomes Res. 2022 Jun;22(4):529-41. doi: 10.1080/14737167.2022.2035219

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022 Jun;40(6):601-32116. doi: 10.1007/s40273-021-01112-8

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy. 2022 Mar;20(2):213-21. doi: 10.1007/s40258-021-00704-x

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. J Manag Care Spec Pharm. 2022 Feb;28(2):146-55. doi: 10.18553/jmcp.2022.cheers

Husereau D, Drummond M, Augustovski F, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, de Bekker-Grob E, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG. 2022 Feb;129(3):336-44. doi: 10.1111/1471-0528.17012

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022 Jan 12;20(1):23. doi: 10.1186/s12916-021-02204-0

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswel C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu R-F, Staniszewska S, the CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022 Jan 11;376:e067975. doi: 10.1136/bmj-2021-067975

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy Pract. 2022 Jan 11;7(1). doi: 10.1177/23814683211061097

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Int J Technol Assess Health Care. 2022 Jan 11;38(1):e13. doi: 10.1017/S0266462321001732

Mauskopf J, Blake L, Eiden A, Roberts C, Hu T, Nyaku M. Economic evaluation of vaccination programs: a guide for selecting modeling approaches. Value Health. 2022 Jan 10. doi: 10.1016/j.jval.2021.10.017

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022 Jan;25(1):3-9. doi: 10.1016/j.jval.2021.11.1351

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022 Jan;25(1):10-31. doi: 10.1016/j.jval.2021.10.008

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. J Med Econ. 2022 Jan;25(sup1):1-7. doi: 10.1080/13696998.2021.2014721

Anderson S, Mauskopf J, Talbird SE, White A, Meenakshi S. Antiseizure medications and oral contraceptives: impact of enzyme inducers on pregnancy outcomes and costs. Epilepsy Behav. 2021 Dec;125:108368. doi: 10.1016/j.yebeh.2021.108368

Mauskopf J, Beck E, Postma M, Devlin N. Expanding the notion of value of new health technologies: should preventive interventions be differently considered than therapeutics? Presentation to be given at the Virtual ISPOR Europe 2021; December 1, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Bracher M, Birch H. Common symptoms in hospitalized COVID-19 patients by age, severity and survival outcome – A literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Han E, Lu E, Heyes A, Mauskopf J, Birch H, Bracher M. The use of pharmacological therapies in hospitalized COVID-19 patients – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Lu E, Han E, Heyes AE, Mauskopf J, Bracher MG, Birch HJ. Economic burden associated with clinical management of COVID-19 – a literature review. Poster presented at the ERS International Congress 2021; September 5, 2021.

Mauskopf JA, Mullins CD, Earnshaw SR. Budget impact analysis: a 6-step approach. Presented at the Saudi Ministry of Health; April 2021.

Earnshaw SR, Mauskopf JA, Mullins CD, Brodtkorb T-H. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Virtual Short Course Progam; February 3, 2021. Previously presented at the 2015 ISPOR 18th Annual European Congress.

Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021 Jan 1;24(1):86-90.

Huang L, Mauskopf J, Farkouh R, Masaquel C. Use of cost-effectiveness analyses for decisions about vaccination programs for meningococcal disease in the United States, United Kingdom, The Netherlands, and Canada. Expert Rev Vaccines. 2021 Jan;20(1):59-72. doi: 10.1080/14760584.2021.1878030

Heyes AE, Nuabor WA, Costello JJ, Mauskopf JM, Petitiean A, Andrew MK. Posthospitalisation outcomes in older patients hospitalised for influenza: a comprehensive literature review. Poster presented at the 2020 Virtual 7th ESWI Influenza Conference; December 6, 2020.

Mauskopf J, Earnshaw S. Budget-impact analyses. In: Rascati, K, editors. Essentials of pharmacoeconomics: health economics and outcomes research. 3rd ed. Alphen aan den Rijn: The Netherlands. Wolters Kluwer; 2020.

Huang L, Masaquel C, Mauskopf J. Targeted review to understand the evolution of national meningococcal vaccination recommendations in four countries. Poster presented at the 2020 European Society for Paediatric Infectious Diseases (ESPID) Virtual Meeting; October 26, 2020.

Mauskopf J, Annemans L. Budget impact analysis. In: Arnold, RJG, editors. Pharmacoeconomics from theory to practice. 2nd ed. Boca Raton: FL. CRC Press; 2020. p.137-52.

Herring WL, Mauskopf J. Persistent challenges in Alzheimer's disease modeling: pragmatic solutions to inform the road forward. Poster presented at the 2020 Alzheimer's Association Virtual International Conference (AAIC); July 2020.

Yi Z, Mauskopf J, Herring W, Graham J. Challenges in estimating eligible population size in budget-impact analyses for new health care technologies. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S288. doi: 10.1016/j.jval.2020.04.371

Mauskopf J, Standaert B, Connolly MP, Jit M, Garrison, Jr. LP, Hutubessy R, Revill P, Severens JL. Economic evaluation of vaccination programs. Presented at the 2020 ISPOR Educational Webinar; January 15, 2020.

Mauskopf J, Fernandez MM, Ghosn J, Sax P, Priest J, Garris C, Clark A. Systematic literature review of multiclass resistance in heavily treatment experienced persons with HIV. Poster presented at the 2019 ID Week Conference; October 5, 2019. Washington, DC. [abstract] Open Forum Infect Dis. 2019 Oct; 6((Suppl 2)):S871. doi: 10.1093/ofid/ofz360.2188

Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, Endel G, Wilbacher F, Malbaski N, Popper N, Chhatwal J, Greenberg D, Mauskopf J, Siebert U. Budget impact analysis of cancer screening: A methodological review. Appl Health Econ Health Policy. 2019 Aug;17(4):493-511. doi: 10.1007/s40258-019-00475-6

Mauskopf JM, Herring WL, Zhang Y, Tahami Monfared AA. The variability in input parameter values in models estimating the effectiveness of hypothetical disease modifying treatments for Alzheimer's Disease. Poster presented at the 2019 Alzheimer's Association International Conference; July 14, 2019. Los Angeles, CA.

Mauskopf J, Herring W, Zhang Y, Tahami A. The variability in structural assumptions in models estimating the effectiveness of hypothetical disease modifying treatment for Alzheimer's Disease. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Drummond M, Hay J, Mauskopf J, Mullins CD. Back to the future in Value in Health. Presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.

Mauskopf JA, Mullins D, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2019 ISPOR 24th Annual International Meeting; May 19, 2019. New Orleans, LA. Previously presented at the ISPOR 18th Annual European Congress.

Mauskopf J. Multivariable and structural uncertainty analysis for cost-effectiveness estimates: back to the future. Value Health. 2019 May;22(5):570-4.

Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801

Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic analysis of vaccination programs. Value Health. 2018 Oct;21(10):1133-49. doi: 10.1016/j.jval.2018.08.005

Mauskopf J, Gharaibeh M, Wamble D, Collier DH, Stolshek BS, Matteson EL. Simulating population disability outcomes for alternative treatment pathways in patients with active rheumatoid arthritis. Poster presented at the 2018 ACR/ARHP Annual Meeting; October 22, 2018. Chicago, IL. [abstract] Arthritis Rheumatol. 2018 Sep; 70(S9):1687-8. doi: 10.1002/art.40700

Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine. 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736

Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, Chhatwal J, Greenberg D, Mauskopf J, Siebert U. Assessment of current use of budget impact analyses for the evaluation of cancer screening programs. Poster presented at the SMDM 17th Biennial European Conference 2018; June 12, 2018. Leiden, The Netherlands.

Mauskopf J, Bloom D, Cicchetti A. Economic evaluation of vaccination programs: exploring multiple methods. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 21, 2018. Baltimore, MD.

Mauskopf J, Mullins CD, Earnshaw SR. Budget impact analysis I: a 6-step approach. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 20, 2018. Baltimore, MD. Previously presented at the ISPOR 18th Annual European Congress.

Brogan AP, Mauskopf J. US payer perspectives on value and comparisons outside the US: an interview study. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Supp 1):S93. doi: 10.1016/j.jval.2018.04.627

Towse A, Mauskopf JA. Affordability of new technologies: the next frontier - Editorial. Value Health. 2018 Mar;21(3):249-51. doi: 10.1016/j.jval.2018.01.011

Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges - Editorial. Eur J Health Econ. 2018 Mar;19(2):173-5. doi: 10.1007/s10198-017-0933-3

Ajmera MR, Boscoe A, Mauskopf J, Candrilli SD, Levy M. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. J Neurol Sci. 2018 Jan;384(2018):96-103. doi: 10.1016/j.jns.2017.11.022

Parikh RC, McLaurin KK, Margulis AV, Mauskopf J, Ambrose CS, Pavilack M, Candrilli SD. Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther. 2017 Dec;6(4):477-86. doi: 10.1007/s40121-017-0167-9

Jahn B, Todorovic J, Bundo M, Sroczynski G, Conrads-Frank A, Rochau U, Chhatwal J, Mauskopf J, Siebert U. Do budget impact analyses for screening of cancers follow international guidelines? A systematic review. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 7, 2017. Glasgow, Scotland.